Checking in on Celularity Inc. (CELU) after recent insiders movement


Celularity Inc.’s filing revealed that its Chief Executive Officer Hariri Robert J acquired Company’s shares for reported $17175.0 on Nov 30. In the deal valued at $1.72 per share,10,000 shares were bought. As a result of this transaction, Hariri Robert J now holds 8,074,996 shares worth roughly $ 5.57 million.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Then, Hariri Robert J bought 40,000 shares, generating $68,400 in total proceeds. Upon buying the shares at $1.71, the Chief Executive Officer now owns 8,064,996 shares.

Before that, Hariri Robert J bought 40,000 shares. Celularity Inc. shares valued at $69,600 were divested by the Chief Executive Officer at a price of $1.74 per share. As a result of the transaction, Hariri Robert J now holds 8,024,996 shares, worth roughly $5.54 million.

Morgan Stanley downgraded its Celularity Inc. [CELU] rating to an Underweight from a an Equal-weight in a research note published on Tuesday, January 30, 2023; the price target was decreased to $1 from $5. PT values the company’s stock at a premium of 31.0 to its Tuesday closing price. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who decreased its forecast for the stock in late December from “an Outperform” to “a Perform”. H.C. Wainwright began covering CELU with “Buy” recommendation on June 22, 2022. Truist revised its rating on April 06, 2022. It rated CELU as “a Hold” which previously was an “a Buy”.

Price Performance Review of CELU

On Tuesday, Celularity Inc. [NASDAQ:CELU] saw its stock jump 2.83% to $0.69. On the same session, the stock had its day’s lowest price of $0.66, but rose to a high of $0.72. Over the last five days, the stock has gained 7.47%. Celularity Inc. shares have fallen nearly -46.82% since the year began. Nevertheless, the stocks have fallen -90.10% over the past one year. While a 52-week high of $13.19 was reached on 01/03/23, a 52-week low of $0.58 was recorded on 02/23/23. SMA at 50 days reached $0.9738, while 200 days put it at $2.7675. A total of 1.06 million shares were traded, compared to the trading of 0.53 million shares in the previous session.

Levels Of Support And Resistance For CELU Stock

The 24-hour chart illustrates a support level at 0.6573, which if violated will result in even more drops to 0.6287. On the upside, there is a resistance level at 0.7173. A further resistance level may holdings at 0.7487. The Relative Strength Index (RSI) on the 14-day chart is 37.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0369, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.29%. Stochastics %K at 24.21% indicates the stock is a holding.

How much short interest is there in Celularity Inc.?

A steep rise in short interest was recorded in Celularity Inc. stocks on Jan 30, 2023, growing by 0.77 million shares to a total of 2.49 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 1.72 million shares. There was a rise of 30.92%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 3.58% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.03.

Celularity Inc. [CELU] – Who Are The Largest Shareholders?

In filings from Starr Investment Holdings LLC, it is revealed that the company now owns 15,281,389 shares, or roughly 10.54% of the outstanding CELU shares. Over the last quarter, The Vanguard Group, Inc. purchased 2,077 shares of Celularity Inc., while Geode Capital Management LLC bought 11,387 shares. At present, SSgA Funds Management, Inc. is holding 812,378 shares valued at $0.68 million. Louis-Dreyfus Family Office LLC owned 720,040 shares of the company at the time of its most recent 13F filing, worth $0.6 million.

The most recent change occurred on January 28, 2022 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $9 price target.


Please enter your comment!
Please enter your name here